3,968 results match your criteria: "Liver Center[Affiliation]"
Orphanet J Rare Dis
October 2024
Department of Medicine and UCSF Liver Center, University of California San Francisco, San Francisco, CA, USA.
Cell Metab
October 2024
Liver Center, Massachusetts General Hospital, Boston, MA, USA.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with iron metabolism disorders and ferroptosis, but the mechanisms underlying this association remain unclear. Fudi Wang's group used animal models, human cohorts, and multi-omics data to demonstrate the role of iron imbalance in MAFLD and the therapeutic potential of the iron chelator FerroTerminator 1 (FOT1).
View Article and Find Full Text PDFKidney360
September 2024
Section of Nephrology, Department of Internal Medicine, Yale University and VA Connecticut Healthcare, New Haven, CT, USA.
J Gastroenterol Hepatol
December 2024
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Cancers (Basel)
September 2024
Department of Urology, National Cancer Center, Goyang 10408, Republic of Korea.
J Hepatol
September 2024
Perspectum Ltd, Oxford, UK. Electronic address:
J Clin Invest
September 2024
Department of Bioengineering and Therapeutic Sciences and Liver Center, UCSF, San Francisco, California, USA.
Activated mTORC2/AKT signaling plays a role in hepatocellular carcinoma (HCC). Research has shown that TSC/mTORC1 and FOXO1 are distinct downstream effectors of AKT signaling in liver regeneration and metabolism. However, the mechanisms by which these pathways mediate mTORC2/AKT activation in HCC are not yet fully understood.
View Article and Find Full Text PDFFuture Oncol
November 2024
Department of Internal Medicine, Yonsei Liver Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
JHEP Rep
October 2024
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background & Aims: We investigated the association of physical activity (PA) levels and changes with the risk of hepatocellular carcinoma (HCC) in patients with type 2 diabetes.
Methods: Patients with type 2 diabetes who had undergone health examinations in 2009 and 2011 were enrolled. In total, 1,439,152 patients were included in the analysis.
Can J Gastroenterol Hepatol
September 2024
Department of Internal Medicine and Liver Research Institute Seoul National University College of Medicine, Seoul, Republic of Korea.
Background: This study aimed to examine whether repeated measurements on noninvasive fibrosis scores during follow-up improve long-term nonalcoholic fatty liver disease (NAFLD) outcome prediction.
Methods: A cohort study of 2,280 NAFLD patients diagnosed at the Seoul National University Hospital from 2001 to 2015 was conducted. Multivariable Cox regression models with baseline and designated time-point measurements of the fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) were used to assess the association between these scores and overall mortality, liver-related outcomes, and cardiovascular events.
Clin Mol Hepatol
September 2024
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
J Hepatol
September 2024
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea. Electronic address:
Lancet Gastroenterol Hepatol
December 2024
Department of Pediatrics and Faculty of Medicine Ain Shams University Research Institute (MASRI), Ain Shams University, Cairo, Egypt.
Intern Med
September 2024
Liver Center, Saga University Hospital, Japan.
Cell
October 2024
Department of Biochemistry and Biophysics, University of California, San Francisco (UCSF), San Francisco, CA, USA; Howard Hughes Medical Institute, UCSF, San Francisco, CA, USA. Electronic address:
Ann Intern Med
October 2024
Academia Sinica, Taipei, Taiwan (C.-J.C.).
BMC Pediatr
September 2024
Swiss Pediatric Liver Center, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
Background: Prenatally diagnosed hepatic hilar cysts are a challenging finding for the clinician. They can either be a sign of cystic biliary atresia (BA) or a choledochal cyst (CC), two diagnoses with different postnatal management and prognosis. Based on a case report of four patients, we aim to propose a management algorithm for prenatally diagnosed "hepatic hilar cysts".
View Article and Find Full Text PDFElife
September 2024
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Nat Commun
September 2024
Department of Nutritional Science and Toxicology, College of Natural Resources, University of California Berkeley, Berkeley, CA, 94720, USA.
Interactions between adipose tissue, liver and immune system are at the center of metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. To address the need for an accurate in vitro model, we establish an interconnected microphysiological system (MPS) containing white adipocytes, hepatocytes and proinflammatory macrophages derived from isogenic human induced pluripotent stem cells. Using this MPS, we find that increasing the adipocyte-to-hepatocyte ratio moderately affects hepatocyte function, whereas macrophage-induced adipocyte inflammation causes lipid accumulation in hepatocytes and MPS-wide insulin resistance, corresponding to initiation of metabolic dysfunction-associated steatotic liver disease.
View Article and Find Full Text PDFJ Public Health Manag Pract
January 2025
Author Affiliations: Alameda County Public Health Department (Dr Yette, Ms Marusinec, and Drs Conlon and Chitnis), Division of Communicable Disease Control and Prevention, San Leandro, CA; Asian Liver Center, Department of Surgery (Drs Pham, Toy, and So), Division of Gastroenterology and Hepatology (Dr Wong), Stanford University School of Medicine, Palo Alto, CA; and Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA (Dr Wong).
Context: In the United States, chronic hepatitis B (CHB) virus infection predominantly affects ethnic minorities and vulnerable populations.
Objective: We analyzed surveillance data to describe CHB epidemiology to guide hepatitis B virus (HBV) elimination efforts in Alameda County.
Design: Persons with CHB during 2017-2021 were identified by ≥2 positive HBV tests (ie, HBsAg, HbeAg, and HBV DNA) ≥180 days apart using data from California Reportable Disease Information Exchange.
Gastroenterology
September 2024
Liver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, Connecticut. Electronic address:
A consistent feature of chronic liver diseases and the hallmark of pathologic repair is the so-called "ductular reaction." This is a histologic abnormality characterized by an expansion of dysmorphic cholangiocytes inside and around portal spaces infiltrated by inflammatory, mesenchymal, and vascular cells. The ductular reaction is a highly regulated response based on the reactivation of morphogenetic signaling mechanisms and a complex crosstalk among a multitude of cell types.
View Article and Find Full Text PDFVideoGIE
August 2024
Gastroenterology Service Intesto, Bern, Switzerland.
J Atheroscler Thromb
September 2024
Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University.
Aims: Cardiovascular disease (CVD) is a common cause of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, CVD surveillance is important, but it is not well established. We evaluated the association between liver fibrosis, carotid artery atherosclerosis, and coronary artery stenosis in patients with MASLD.
View Article and Find Full Text PDFBlood Adv
November 2024
Center for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy.
Adeno-associated virus-based gene therapy (valoctocogene roxaparvovec) is an attractive treatment for hemophilia A. Careful clinical management is required to minimize the risk of hepatotoxicity, including assessment of baseline liver condition to determine treatment eligibility and monitoring liver function after gene therapy. This article describes recommendations (developed by a group of hemophilia experts) on hepatic function monitoring before and after gene therapy.
View Article and Find Full Text PDFDig Dis Sci
October 2024
Gastrointestinal Unit, Gastrointestinal Division, Department of Medicine, Liver Center, Massachusetts General Hospital, Boston, MA, USA.